S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SNDX Syndax Pharmaceuticals Inc

13.20

0.40 (3.13%)

Pre Market

Last Updated: 03:02:08

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals Inc News

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Wednesday 15 January 2025 (12 hours ago) • PR Newswire (US)

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 13 January 2025 (3 days ago) • PR Newswire (US)

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Tuesday 7 January 2025 (1 week ago) • PR Newswire (US)

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 7 January 2025 (1 week ago) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Friday 3 January 2025 (2 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Friday 20 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Monday 9 December 2024 (1 month ago) • PR Newswire (US)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Saturday 7 December 2024 (1 month ago) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tuesday 3 December 2024 (1 month ago) • PR Newswire (US)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Wednesday 27 November 2024 (2 months ago) • PR Newswire (US)

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Friday 15 November 2024 (2 months ago) • PR Newswire (US)

More Syndax Pharmaceuticals Inc News Articles

Good Vibrations Shoes (PK)

Moon Equity (PK)

Brookmount Explorations (PK)

Decentral Life (PK)

Kraig Biocraft Laborator... (QB)

Enanta Pharmaceuticals

Tonix Pharmaceuticals

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions